Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE ® bioreactor

Robert P.T. Somerville; Laura Devillier; Maria R. Parkhurst; Steven A. Rosenberg; Mark E. Dudley

doi:10.1186/1479-5876-10-69

Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE ^®bioreactor

Robert P.T. Somerville, Laura Devillier, Maria R. Parkhurst, Steven A. Rosenberg, Mark E. Dudley

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Background: To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE ^®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.Methods: We have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.Results: TIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.Conclusions: The WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under GMP conditions, and provides an alternate approach to cell generation for ACT protocols.

Original language	English (US)
Article number	69
Journal	Journal of translational medicine
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/1479-5876-10-69
State	Published - Apr 4 2012
Externally published	Yes

Keywords

Adoptive immunotherapy
Human
T cell receptors
T cells
Tumor immunity

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1186/1479-5876-10-69

Cite this

@article{3d4a5b57d117440295f2f3cb6d3bba29,

title = "Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE {\textregistered} bioreactor",

abstract = "Background: To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE {\textregistered}, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.Methods: We have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.Results: TIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.Conclusions: The WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under GMP conditions, and provides an alternate approach to cell generation for ACT protocols.",

keywords = "Adoptive immunotherapy, Human, T cell receptors, T cells, Tumor immunity",

author = "Somerville, {Robert P.T.} and Laura Devillier and Parkhurst, {Maria R.} and Rosenberg, {Steven A.} and Dudley, {Mark E.}",

note = "Funding Information: This research was supported in part by the intramural research program of the National Cancer Institute. Robert Somerville is supported by the Adelson Medical Research Foundation. We would like to thank Kate Hogan, Michelle Langhan, Thomas Shelton, Azam Nahvi, Linda Parker, Colin Gross and Marcos Garcia for assisting with this research.",

year = "2012",

month = apr,

day = "4",

doi = "10.1186/1479-5876-10-69",

language = "English (US)",

volume = "10",

journal = "Journal of translational medicine",

issn = "1479-5876",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE ® bioreactor

AU - Somerville, Robert P.T.

AU - Devillier, Laura

AU - Parkhurst, Maria R.

AU - Rosenberg, Steven A.

AU - Dudley, Mark E.

N1 - Funding Information: This research was supported in part by the intramural research program of the National Cancer Institute. Robert Somerville is supported by the Adelson Medical Research Foundation. We would like to thank Kate Hogan, Michelle Langhan, Thomas Shelton, Azam Nahvi, Linda Parker, Colin Gross and Marcos Garcia for assisting with this research.

PY - 2012/4/4

Y1 - 2012/4/4

N2 - Background: To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE ®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.Methods: We have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.Results: TIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.Conclusions: The WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under GMP conditions, and provides an alternate approach to cell generation for ACT protocols.

AB - Background: To simplify clinical scale lymphocyte expansions, we investigated the use of the WAVE ®, a closed system bioreactor that utilizes active perfusion to generate high cell numbers in minimal volumes.Methods: We have developed an optimized rapid expansion protocol for the WAVE bioreactor that produces clinically relevant numbers of cells for our adoptive cell transfer clinical protocols.Results: TIL and genetically modified PBL were rapidly expanded to clinically relevant scales in both static bags and the WAVE bioreactor. Both bioreactors produced comparable numbers of cells; however the cultures generated in the WAVE bioreactor had a higher percentage of CD4+ cells and had a less activated phenotype.Conclusions: The WAVE bioreactor simplifies the process of rapidly expanding tumor reactive lymphocytes under GMP conditions, and provides an alternate approach to cell generation for ACT protocols.

KW - Adoptive immunotherapy

KW - Human

KW - T cell receptors

KW - T cells

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=84859179612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859179612&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-69

DO - 10.1186/1479-5876-10-69

M3 - Article

C2 - 22475724

AN - SCOPUS:84859179612

SN - 1479-5876

VL - 10

JO - Journal of translational medicine

JF - Journal of translational medicine

IS - 1

M1 - 69

ER -